for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aethlon Medical, Inc.

AEMD.OQ

Latest Trade

2.70USD

Change

0.09(+3.45%)

Volume

462

Today's Range

2.61

 - 

2.70

52 Week Range

2.61

 - 

26.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aethlon Medical Posts Q2 Loss Of $1.29/Shr

Nov 1 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.29.AT SEPTEMBER 30, 2019, COMPANY HAD A CASH BALANCE OF APPROXIMATELY $800,000.

Aethlon Announces Reverse Stock Split

Oct 14 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON ANNOUNCES REVERSE STOCK SPLIT.AETHLON MEDICAL INC - BOARD OF DIRECTORS APPROVED A 1-FOR-15 REVERSE STOCK SPLIT.AETHLON MEDICAL - SHARES TO BEGIN TRADING ON SPLIT-ADJUSTED BASIS COMMENCING UPON MARKET OPENING ON OCT. 15.

Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications

Oct 7 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL ANNOUNCES FDA APPROVAL OF IDE FOR ONCOLOGY INDICATIONS.

Aethlon Medical Says National Cancer Institute Awarded Co SBIR Phase 2 Contract For Topic 359

Sept 16 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL RECEIVES NATIONAL CANCER INSTITUTE CONTRACT AWARD.AETHLON MEDICAL - NATIONAL CANCER INSTITUTE AWARDED CO SBIR PHASE 2 CONTRACT FOR TOPIC 359.AETHLON MEDICAL INC - TOTAL AMOUNT OF FIRM FIXED PRICE CONTRACT IS $1.86 MILLION.AETHLON MEDICAL INC - NCI PHASE II CONTRACT PERIOD RUNS FROM SEPTEMBER 16, 2019 THROUGH SEPTEMBER 15, 2021.

Aethlon Medical Says Q1 Loss Per Share $0.11

Aug 14 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.11.

Aethlon Medical Inc Files For Mixed Shelf Of Up To $5 Million

May 10 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL INC FILES FOR MIXED SHELF OF UP TO $5 MILLION – SEC FILING.

Aethlon Medical - Received A Letter From Nasdaq Indicating Co Failed To Comply With Minimum Bid Price Requirement Of Nasdaq Listing Rule

May 8 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL - ON MAY 2 RECEIVED A LETTER FROM NASDAQ INDICATING CO FAILED TO COMPLY WITH MINIMUM BID PRICE REQUIREMENT OF NASDAQ LISTING RULE.

Aethlon Medical Says Working On Executing Plan To Advance Co's Unique Hemopurifier Through Clinical Trials & Regulatory Approvals

April 17 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL INC - WORKING ON EXECUTING A PLAN TO ADVANCE AETHLON'S UNIQUE HEMOPURIFIER THROUGH CLINICAL TRIALS AND REGULATORY APPROVALS.AETHLON MEDICAL - TO FOCUS PRIMARY DEVELOPMENT EFFORTS IN CANCER WHERE EXOSOMES CAN BE REMOVED BY HEMOPURIFIER .AETHLON MEDICAL INC - NOW COMMUNICATING WITH FDA AND PREPARING FOR CLINICAL TRIALS IN CANCER.

Aethlon Medical Reports Q3 Loss Per Share $0.11

Feb 11 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON MEDICAL ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.11.

Aethlon Announces Appointment Of Timothy Rodell As Interim CEO

Dec 13 (Reuters) - Aethlon Medical Inc <AEMD.O>::AETHLON ANNOUNCES APPOINTMENT OF TIMOTHY RODELL AS INTERIM CHIEF EXECUTIVE OFFICER.AETHLON MEDICAL INC - RODELL SUCCEEDS JAMES JOYCE, WHO WILL SERVE AS A CONSULTANT TO AETHLON DURING TRANSITION.AETHLON MEDICAL INC - RODELL JOINS AETHLON FROM GLOBEIMMUNE, INC. WHERE HE WAS PRESIDENT, AND CHIEF EXECUTIVE OFFICER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up